Home > Platform Technologies

Cytogel has a portfolio of novel analgesic product candidates and broadly useful polymer and hydrogel drug delivery platform technologies. Cytogel owns intellectual property for a number of highly active opioid analgesics from the endomorphin (EM) family of compounds. These agents are the first of an entirely new class of drugs. The Company's drug delivery technologies were acquired from Cornell University, and patents have been issued on hydrogels and injectible microspheres. Cytogel will develop products from these platform technologies to the point of demonstrated value and then license these products to other larger companies for the full scientific and clinical development and subsequent commercialization.